Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) is a major complication of preterm birth and has serious adverse long-term health consequences. The etiology of BPD is complex, multifactorial, and incompletely understood. Contributing factors include ventilator-induced lung injury, exposure to toxic oxygen levels, and infection. Several preventive and therapeutic strategies have been developed with variable success. These include lung protective ventilator strategies and pharmacological and nutritional interventions. These strategies target different components and stages of the disease process and they are commonly used in combination. The purpose of this review is to discuss the evidence for current pharmacological interventions and identify future therapeutic modalities that appear promising in the prevention and management of BPD. Continued improved understanding of BPD pathogenesis leads to opportunities for newer preventive approaches. These will need to be evaluated in the setting of current clinical practice in order to assess their efficacy.

[1]  I. Liener,et al.  Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. , 2015, The American review of respiratory disease.

[2]  L. Doyle,et al.  Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2014, The Cochrane database of systematic reviews.

[3]  A. Ohlsson,et al.  Inositol for respiratory distress syndrome in preterm infants. , 2012, The Cochrane database of systematic reviews.

[4]  R. Ehrenkranz,et al.  Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials , 2011, Pediatrics.

[5]  L. Brion,et al.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. , 2011, The Cochrane database of systematic reviews.

[6]  L. Brion,et al.  Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. , 2011, The Cochrane database of systematic reviews.

[7]  M. Walsh,et al.  Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. , 2011, American journal of respiratory and critical care medicine.

[8]  Renee F Wilson,et al.  Inhaled Nitric Oxide in Preterm Infants: A Systematic Review , 2011, Pediatrics.

[9]  D. Rowitch,et al.  NIH Consensus Development Conference Statement: Inhaled Nitric-Oxide Therapy for Premature Infants , 2011, Pediatrics.

[10]  David J Henderson-Smart,et al.  Methylxanthine treatment for apnoea in preterm infants. , 2010, The Cochrane database of systematic reviews.

[11]  A. Greenough,et al.  Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial , 2010, The Lancet.

[12]  M. Matthay,et al.  Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia: delivering the secretome. , 2009, American journal of respiratory and critical care medicine.

[13]  M. Laughon,et al.  Prevention of bronchopulmonary dysplasia. , 2009, Seminars in fetal & neonatal medicine.

[14]  O. Liang,et al.  Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. , 2009, American journal of respiratory and critical care medicine.

[15]  S. Archer,et al.  Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. , 2009, American journal of respiratory and critical care medicine.

[16]  W. Thomas,et al.  Nonventilatory Strategies for Prevention and Treatment of Bronchopulmonary Dysplasia – What Is the Evidence? , 2008, Neonatology.

[17]  E. Eichenwald,et al.  Management and outcomes of very low birth weight. , 2008, The New England journal of medicine.

[18]  D. Henderson-smart,et al.  Methylxanthine treatment for apnea in preterm infants. , 2008, The Cochrane database of systematic reviews.

[19]  L. Doyle,et al.  Long-term effects of caffeine therapy for apnea of prematurity. , 2007, The New England journal of medicine.

[20]  W. Poole,et al.  Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure , 2007, Journal of Perinatology.

[21]  H. Christou,et al.  Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. , 2006, Seminars in perinatology.

[22]  G. Cutter,et al.  Early inhaled nitric oxide therapy in premature newborns with respiratory failure. , 2006, The New England journal of medicine.

[23]  L. Brion,et al.  Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. , 2006, The Cochrane database of systematic reviews.

[24]  L. Doyle,et al.  Caffeine therapy for apnea of prematurity. , 2006, The New England journal of medicine.

[25]  M. Walsh,et al.  Summary Proceedings From the Bronchopulmonary Dysplasia Group , 2006, Pediatrics.

[26]  J. Carlin,et al.  Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial , 2006, Pediatrics.

[27]  R. Mitchell,et al.  The role of stem cells in the response to myocardial and vascular wall injury. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[28]  C. Lachance,et al.  Fluticasone Inhalation in Moderate Cases of Bronchopulmonary Dysplasia , 2005, Pediatrics.

[29]  D. Phinney,et al.  Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. , 2005, Current pharmaceutical design.

[30]  J. Crapo,et al.  Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[31]  B. Vohr,et al.  Vitamin A Supplementation for Extremely Low Birth Weight Infants: Outcome at 18 to 22 Months , 2005, Pediatrics.

[32]  K. Watterberg,et al.  Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial , 2004, Pediatrics.

[33]  V. Fellman,et al.  N-Acetylcysteine Administration during the First Week of Life Does Not Improve Lung Function in Extremely Low Birth Weight Infants , 2004, Neonatology.

[34]  C. Piantadosi,et al.  Discordant extracellular superoxide dismutase expression and activity in neonatal hyperoxic lung. , 2004, American journal of respiratory and critical care medicine.

[35]  A. Jobe,et al.  Choice and dose of corticosteroid for antenatal treatments. , 2004, American journal of obstetrics and gynecology.

[36]  K. Stenmark,et al.  Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis , 2004, The Pediatric infectious disease journal.

[37]  V. Fellman,et al.  N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. , 2003, The Journal of pediatrics.

[38]  J. Marks,et al.  Inhaled nitric oxide in premature infants with the respiratory distress syndrome. , 2003, The New England journal of medicine.

[39]  N. Laird,et al.  Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. , 2003, The Journal of allergy and clinical immunology.

[40]  B. Lipworth,et al.  Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27. , 2003, British journal of clinical pharmacology.

[41]  J. Davis,et al.  Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. , 2003, Pediatrics.

[42]  R. Ehrenkranz,et al.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[43]  R. Ehrenkranz,et al.  Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[44]  R. Ehrenkranz,et al.  Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[45]  J. Cummings,et al.  A Randomized Trial of Inhaled Versus Intravenous Steroids in Ventilator-Dependent Preterm Infants , 2002, Journal of Perinatology.

[46]  M. Kennedy,et al.  Beta-adrenergic receptor polymorphisms and drug responses in asthma. , 2002, Pharmacogenomics.

[47]  P. Gressens,et al.  Neurotoxic Effects of Fluorinated Glucocorticoid Preparations on the Developing Mouse Brain: Role of Preservatives , 2001, Pediatric Research.

[48]  A. Jobe,et al.  Prospects for research in reproductive health and birth outcomes. , 2001, JAMA.

[49]  C. Patterson,et al.  A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. , 2001, Pediatrics.

[50]  S. Wardle,et al.  Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease , 2001, Archives of disease in childhood. Fetal and neonatal edition.

[51]  J. Fiascone,et al.  Strategies for prevention of neonatal chronic lung disease. , 2000, Seminars in perinatology.

[52]  F. Ducharme,et al.  Inhaled steroids for neonatal chronic lung disease. , 1999, The Cochrane database of systematic reviews.

[53]  J. Tyson,et al.  VITAMIN A SUPPLEMENTATION FOR EXTREMELY-LOW-BIRTH-WEIGHT INFANTS , 1999 .

[54]  J. Rychik,et al.  Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. , 1999, Pediatrics.

[55]  A. Denjean,et al.  Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study , 1998, European Journal of Pediatrics.

[56]  E. Bancalari.  Corticosteroids and neonatal chronic lung disease , 1998, European Journal of Pediatrics.

[57]  N. Rifai,et al.  Early High Dose Antioxidant Vitamins Do Not Prevent Bronchopulmonary Dysplasia in Premature Baboons Exposed to Prolonged Hyperosia: APilot Study , 1998, Pediatric Research.

[58]  S. Ryan,et al.  Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants , 1997, Archives of disease in childhood. Fetal and neonatal edition.

[59]  Richard J Martin,et al.  Effect of Exogenous and Endogenous Nitric Oxide on the Airway and Tissue Components of Lung Resistance in the Newborn Piglet , 1997, Pediatric Research.

[60]  C. Poets,et al.  Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease , 1997, Pediatric pulmonology.

[61]  A. Meister,et al.  L-2-oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet. , 1995, The Journal of nutrition.

[62]  D. Ivy,et al.  Inhaled Nitric Oxide Improves Gas Exchange and Lowers Pulmonary Vascular Resistance in Severe Experimental Hyaline Membrane Disease , 1994, Pediatric Research.

[63]  D. Durand,et al.  Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. , 1994, The Journal of pediatrics.

[64]  R. Wilkening,et al.  Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. , 1993, Pediatrics.

[65]  K. Kennedy.  Epidemiology of acute and chronic lung injury. , 1993, Seminars in perinatology.

[66]  C. Aebi,et al.  Respiratory response to salbutamol (albuterol) in ventilator-dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection , 1993, Intensive Care Medicine.

[67]  J. Davis,et al.  Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. , 1993, Journal of applied physiology.

[68]  K. Watterberg,et al.  Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: a pilot study. The Neonatal Cromolyn Study Group. , 1993, Pediatrics.

[69]  K. Hoppu,et al.  Inositol supplementation in premature infants with respiratory distress syndrome. , 1992, The New England journal of medicine.

[70]  K. Barrington,et al.  The Natural History of the Appearance of Apnea of Prematurity , 1991, Pediatric Research.

[71]  A. Zipursky,et al.  Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. , 1991, The European respiratory journal.

[72]  B. Schmidt,et al.  Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia , 1990, Critical care medicine.

[73]  R. Parker,et al.  Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. , 1990, The Journal of pediatrics.

[74]  A. Leviton,et al.  Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. , 1990, The Journal of pediatrics.

[75]  A. Rotschild,et al.  Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. , 1989, The Journal of pediatrics.

[76]  J. Brady,et al.  Controlled trial of furosemide therapy in infants with chronic lung disease. , 1985, The Journal of pediatrics.

[77]  P. Barnes,et al.  Fetal pulmonary beta-adrenergic receptors: characterization in the human and in vitro modulation by glucocorticoids in the rabbit. , 1985, Pediatric pulmonology.

[78]  A. Lazzara,et al.  Pulmonary effects of furosemide in preterm infants with lung disease. , 1983, The Journal of pediatrics.

[79]  A. Stark,et al.  Bronchopulmonary dysplasia: possible relationship to pulmonary edema. , 1978, The Journal of pediatrics.

[80]  Yahya Al Ethawi.  Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation , 2012, Journal of clinical neonatology.

[81]  L. Doyle,et al.  Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2009, The Cochrane database of systematic reviews.

[82]  Richard J Martin.  Long-Term Effects of Caffeine Therapy for Apnea of Prematurity , 2008 .

[83]  B. Darlow,et al.  Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. , 2007, The Cochrane database of systematic reviews.

[84]  H. Halliday,et al.  Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. , 2007, The Cochrane database of systematic reviews.

[85]  R. Ehrenkranz.  Caffeine Therapy for Apnea of Prematurity , 2007 .

[86]  L. Monte,et al.  [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.

[87]  H. Halliday,et al.  Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. , 2003, The Cochrane database of systematic reviews.

[88]  L. Doyle,et al.  Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.

[89]  S. Abbasi,et al.  Pulmonary Function and Electrolyte Balance Following Spironolactone Treatment in Preterm Infants With Chronic Lung Disease: A Double-Blind, Placebo-Controlled, Randomized Trial , 2000, Journal of Perinatology.

[90]  L. Brion,et al.  Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. , 2000, The Cochrane database of systematic reviews.

[91]  D. Henderson-smart,et al.  Methylxanthine treatment for apnea in preterm infants. , 2000, The Cochrane database of systematic reviews.

[92]  J. Hasday,et al.  Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. , 1997, American journal of respiratory and critical care medicine.

[93]  J. Davis,et al.  Drug therapy for bronchopulmonary dysplasia , 1990, Pediatric pulmonology.

[94]  J. Crapo,et al.  Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. , 1984, The Journal of clinical investigation.